Active	Status	Sponsor type	Region	Phase	Filter
5 Active 4 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yang, Jilong
TQB2916-AK105-II-01, NCT06500091: TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors	Not yet recruiting	2	54	RoW	TQB2916 injection + doxorubicin hydrochloride for injection, TQB2916 injection+penpulimab injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Soft Tissue Sarcoma, Melanoma	06/26	12/26
NCT05046314: A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma	Recruiting	2	30	RoW	TK216+Vincristin	Shanghai Pharmaceuticals Holding Co., Ltd	Sarcoma, Ewing	09/25	12/25
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853	Recruiting	1/2	254	US, RoW	HH2853 Tablets	Haihe Biopharma Co., Ltd.	FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor	12/25	12/25
NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.	Recruiting	1/2	63	RoW	SPH4336, Cadonilimab	Shanghai Pharmaceuticals Holding Co., Ltd	Advanced Solid Tumors	05/25	12/25
Cui, Yongxia
NCT05046314: A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma	Recruiting	2	30	RoW	TK216+Vincristin	Shanghai Pharmaceuticals Holding Co., Ltd	Sarcoma, Ewing	09/25	12/25